Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

Item

http://www.wikidata.org/entity/Q34150635

Q34150635

about

Current status of biomarker research in neurology Advances in the treatment of newly diagnosed glioblastoma Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Treatment options and outcomes for glioblastoma in the elderly patient Oligodendroglioma: pathology, molecular mechanisms and markers Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2 ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.Patient-specific mathematical neuro-oncology: using a simple proliferation and invasion tumor model to inform clinical practice Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification The epidemiology of glioma in adults: a "state of the science" review Epidemiologic and molecular prognostic review of glioblastoma High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing Surgical management of high-grade glioma: a standard of care.Non-invasive metabolic imaging of brain tumours in the era of precision medicine.Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma Prognostic value of the preoperative immunological profile in patients with glioblastoma.Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.Assessment and treatment relevance in elderly glioblastoma patients.The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial Screening for EGFR amplifications with a novel method and their significance for the outcome of glioblastoma patients.Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival microRNA-124 inhibits migration and invasion by down-regulating ROCK1 in glioma.IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas.IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.Glioma-derived T cell immunoglobulin- and mucin domain-containing molecule-4 (TIM4) contributes to tumor tolerance Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.How molecular testing can help (and hurt) in the workup of gliomas.A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells.

P2860

Q26744505-5576D771-BABC-4009-86D6-7852857F2126 Q26773514-F173AF9C-93B4-4EC8-BF16-F7C1BF2EEF76 Q26822717-59A0B50D-70B2-4DEB-9D03-727DFF2D4E49 Q26825769-92908264-3EA5-4151-B381-70216DF8F2C0 Q26853516-722F7155-F363-4C50-B992-8179C837C0A3 Q26991605-3C2F4E61-1C9F-4BEE-BBC7-E16C02C8248D Q27002448-F17383E9-70AE-4C65-B104-09E552546334 Q27010096-C65DB6BF-58BB-4619-84CA-A973C7A6CD79 Q27852494-7788841F-F5AA-4348-B4FA-6C24A86021DA Q28083949-C0443941-AD81-4805-9ED0-D3CBCCD0CA56 Q28088458-98A652CF-2C69-44B9-8CAD-836BC8B6CDE1 Q28383205-FEE27605-902D-4428-9C49-ED8EE43DB21D Q28387839-97DBBEE5-3782-4C66-BBAC-30C5A1CE186A Q28395302-16EFB6DE-82B4-4375-9664-DA337D0E4A25 Q28486219-8601F38D-46A5-470A-8991-0074604F3F53 Q30572884-C18FE93A-32E9-4A38-AE23-0CB33033E1A5 Q30810936-9E6CDC6D-35CB-4CFB-8487-78EC0C2721B4 Q30838365-0991F954-A437-40ED-8BE7-C55D7B583A34 Q31115540-93C96D3E-3C40-4124-95E7-92C767F7D848 Q33419628-F0B815F0-D3D3-4415-9727-C4AB0E374AFD Q33597773-81490071-193B-455D-A57B-39FF2C5E94D7 Q33753426-5E223A62-9A3A-47E5-AD2B-F150604C7A29 Q33804713-B149931C-DC02-4B2C-ABC1-A6148BF60B9C Q33868332-51D53F9B-DED6-4B9D-8E46-501B2A0292C0 Q33887213-E0B66049-F364-400A-832A-36F194D5740A Q33925544-FE89DF9B-78CE-4625-BAA6-6D9626FB8CB3 Q34061985-0029AD88-0F9D-46DB-B221-E400B5F7334A Q34359650-85314F14-151C-4CDE-9048-69BE07C5FAF8 Q34498352-6E6B526F-7C62-4359-9432-6549739E0783 Q34500050-35E172A2-DF27-458A-8998-E1385C1B8952 Q34769934-B5513B9E-5E5C-4B80-B220-4CA8DEF32DF6 Q34807321-985A9DAA-74BB-4D46-B85A-2CE7B9132E0D Q34920251-FB237115-ABCA-44C8-AA75-9F7032FF1C67 Q35059157-9F9B13F2-5D93-4B1F-987D-263FA5E11080 Q35077834-C1F08FE9-5EEF-4245-9F05-DAD4C1BE05FC Q35204658-EA236A67-6FB4-4AD4-9B09-EBF4A01E5F40 Q35378998-F1E757F2-1FD6-4109-A61D-C81B0F187257 Q35441165-C9357D8E-004F-4B22-B8F9-46CC36AA86F2 Q35770275-5DE3DCF2-11B2-4600-8F25-68048B88BBEC Q35782988-28DA46D5-FCEB-4635-8B4A-3ED76B326FCC

P2860

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

Item

http://www.wikidata.org/entity/Q34150635

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu